Editorial introduction : Current Opinion in HIV and AIDS

Secondary Logo

Journal Logo

EDITORIAL INTRODUCTION

Editorial introduction

Editor(s): Mothe, Beatriz

Current Opinion in HIV and AIDS: November 2022 - Volume 17 - Issue 6 - p v
doi: 10.1097/COH.0000000000000762
  • Free

Current Opinion in HIV and AIDS was launched in 2006. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of HIV and AIDS are divided into nine sections that are reviewed once a year. Each section is assigned one or two Section Editors, leading authorities in the area, who identify the most important topics at that time. Here we are pleased to introduce the Journal's Section Editor for this issue.

SECTION EDITOR

Beatriz Mothe

figure1
Beatriz Mothe

Dr Mothe is a clinical investigator at the HIV unit of the Infectious Diseases Department of the Hospital Germans Trias I Pujol since 2007. She keeps a part-time activity as an ID physician in the HIV unit and at IrsiCaixa AIDS Research Institute as an associate investigator. She has actively participated in the design (inventorship), pre-clinical and clinical testing of a novel HIV T-cell immunogen that is designed to redirect CTL responses towards protective and conserved HIV targets able to control viral replication. She focuses her clinical activity on the identification and early treatment of acute/recent HIV infection and monitoring of HIV controller cohorts while designing and coordinating clinical trials and their immunomonitoring in the areas of therapeutic vaccines and eradication strategies, reflecting her translational profile. She has been the principal investigator of several therapeutic vaccine trials tested alone or in combination cure strategies. She has recently contributed to the International AIDS Society Global Scientific Strategy 2021. Since 2019 she has expanded her research to COVID19 vaccine immunogenicity studies in individuals with underlying immunosuppressive conditions and, currently, to monkeypox as well.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.